Chongqing Lummy Pharmaceutical Market Cap ($1.60 Billion)
Market Cap & Net Worth: Chongqing Lummy Pharmaceutical (300006)
Chongqing Lummy Pharmaceutical market cap. Chongqing Lummy Pharmaceutical (SHE:300006) has a market capitalization of $1.60 Billion (CN¥10.93 Billion) as of November 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #6730 globally and #1317 in its home market, demonstrating a 32.35% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Chongqing Lummy Pharmaceutical's stock price CN¥10.35 by its total outstanding shares 1055911205 (1.06 Billion). Also see 300006 cash flow conversion for how efficiently the company converts equity into cash flow.
Chongqing Lummy Pharmaceutical Market Cap History (2015–2026)
Chongqing Lummy Pharmaceutical market cap history from 2015 to 2026. Data shows growth from $1.65 Billion to $1.60 Billion (2.38% CAGR). Check 300006 stock price and chart for real-time trading data and today's change.
Chongqing Lummy Pharmaceutical Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Chongqing Lummy Pharmaceutical's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Chongqing Lummy Pharmaceutical (300006) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.71x
Chongqing Lummy Pharmaceutical's market cap is 0.71 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.65 Billion | $963.98 Million | $20.61 Million | 1.71x | 79.89x |
| 2016 | $1.26 Billion | $990.22 Million | $6.98 Million | 1.27x | 179.88x |
| 2017 | $952.53 Million | $1.28 Billion | $55.56 Million | 0.74x | 17.14x |
| 2018 | $545.69 Million | $1.56 Billion | $98.00 Million | 0.35x | 5.57x |
| 2019 | $864.73 Million | $1.86 Billion | -$155.20 Million | 0.47x | N/A |
| 2020 | $1.15 Billion | $1.58 Billion | -$326.76 Million | 0.72x | N/A |
| 2021 | $1.05 Billion | $1.23 Billion | -$100.53 Million | 0.86x | N/A |
| 2022 | $588.69 Million | $884.59 Million | -$68.71 Million | 0.67x | N/A |
| 2023 | $574.79 Million | $895.59 Million | -$8.93 Million | 0.64x | N/A |
| 2024 | $565.52 Million | $795.60 Million | -$87.80 Million | 0.71x | N/A |
Competitor Companies of 300006 by Market Capitalization
Companies near Chongqing Lummy Pharmaceutical in the global market cap rankings as of November 4, 2026. Also see Chongqing Lummy Pharmaceutical (300006) total assets for a full breakdown of the balance sheet.
Key companies related to Chongqing Lummy Pharmaceutical by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #12 globally with a market cap of $1.06 Trillion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #20 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #29 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #42 globally with a market cap of $356.49 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #12 | Eli Lilly and Company | NYSE:LLY | $1.06 Trillion | $1410.99 |
| #20 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #29 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $270.56 |
| #42 | AbbVie Inc | NYSE:ABBV | $356.49 Billion | $288.84 |
Market Capitalization of Chongqing Lummy Pharmaceutical (2015–2026)
Market capitalization of Chongqing Lummy Pharmaceutical from 2015 to today. Between 2015 and today, Chongqing Lummy Pharmaceutical's market cap moved from $1.65 Billion to $ 1.60 Billion, with a yearly change of 2.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.60 Billion | +101.36% |
| 2025 | CN¥794.20 Million | +40.44% |
| 2024 | CN¥565.52 Million | -1.61% |
| 2023 | CN¥574.79 Million | -2.36% |
| 2022 | CN¥588.69 Million | -44.13% |
| 2021 | CN¥1.05 Billion | -8.21% |
| 2020 | CN¥1.15 Billion | +32.76% |
| 2019 | CN¥864.73 Million | +58.46% |
| 2018 | CN¥545.69 Million | -42.71% |
| 2017 | CN¥952.53 Million | -24.15% |
| 2016 | CN¥1.26 Billion | -23.74% |
| 2015 | CN¥1.65 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Chongqing Lummy Pharmaceutical was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.60 Billion USD |
| MoneyControl | $1.60 Billion USD |
| MarketWatch | $1.60 Billion USD |
| marketcap.company | $1.60 Billion USD |
| Reuters | $1.60 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Chongqing Lummy Pharmaceutical
Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. It provides anti-tumor, anti-inflammatory, antibacterial, digestive, anti-virus, blood system, cardiovascular system, acid-base balance nutritional medicine, endocrine system drugs, tumor adjuvant medication, antifungal, and opioid receptor antagonists. Chon… Read more